pembrolizumab,sunitinib,osimertinib
astrazeneca,merck,pfizer
['pembro', 'melanoma', 'sunitinib', 'osimertinib', 'sclc', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', 'nsclc', 'kn-564', 'aura ,(-laura)']
adjuvant therapies in renal cell carcinoma: are new data practice changing? by matthew r. zibelman, md diferences between trials and outcomes. remarkable #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.